What You Should Know:
– Huma Therapeutics (“Huma”), a global leader in healthcare AI accelerating digital transformation across care and research, today unveiled two significant strategic advancements: a global partnership agreement with Eckuity Capital and the acquisition of Aluna (also known as Knox Medical Diagnostics, Inc.). These moves are set to bolster Huma’s capabilities in developing next-generation technology infrastructure and expand its reach in specialized disease management, particularly in respiratory health.
– The collaboration with Eckuity Capital will focus on creating a robust framework for the acquisition and launch of digital solutions in healthcare and research, built on strong regulatory foundations.
– The acquisition of Aluna, a U.S.-based company specializing in intelligent remote monitoring for respiratory diseases, significantly strengthens Huma’s offerings in this critical care area.
Fueling Expansion Through Strategic Partnership and M&A
To power its continued growth and an aggressive M&A strategy, Huma is partnering with Eckuity Capital, a leading healthcare growth equity firm. This collaboration aims to provide the necessary resources for Huma to acquire complementary companies, thereby building a comprehensive digital ecosystem to support health systems, pharmaceutical companies, Contract Research Organizations (CROs), and patients globally.
Huma’s award-winning, disease-agnostic cloud platform has already achieved major regulatory certifications, including FDA 510(k) Class II and EU MDR Class IIb status. It currently supports over 4,500 hospitals and clinics and engages more than 50 million individuals across over 70 countries, playing a pivotal role in national healthcare initiatives in the U.S., U.K., Germany, Greece, and Saudi Arabia.
Strengthening Respiratory Health Capabilities with Aluna Acquisition
The acquisition of San Francisco-based Aluna marks a significant expansion of Huma’s footprint in respiratory health. Aluna is a market leader in respiratory patient monitoring and medical device manufacturing, including its proprietary peak flow meters, and brings with it a network of over 150 U.S.-based health systems and clinics.
As part of the integration, Aluna’s solutions will be relaunched on the Huma Cloud Platform. This migration is expected to enhance their capabilities, leveraging the Huma platform’s seamless, code-free configuration and AI/ML integration across various disease areas. The upgrade will also elevate Aluna’s product classification to FDA Class II, unlocking greater clinical value. Importantly, all existing Aluna customers will gain access to Huma’s comprehensive portfolio of disease management programs—spanning asthma, COPD, sleep apnea, and related conditions—which currently serve approximately 500,000 contracted lives.
This strategic move positions Huma to better serve the more than 25 million asthma patients and 15 million COPD patients in the United States alone, while reinforcing its leadership in chronic respiratory care on a global scale.
Charvi Shetty, CEO of Aluna, expressed enthusiasm for the merger: “Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide. We are excited about the prospect of integrating our technology into the Huma Cloud Platform, creating a truly holistic digital health solution that empowers both patients and healthcare professionals in the effective management of respiratory conditions.”
